JP2022151438A - Agents for treating conchitis and tympanitis - Google Patents
Agents for treating conchitis and tympanitis Download PDFInfo
- Publication number
- JP2022151438A JP2022151438A JP2021081962A JP2021081962A JP2022151438A JP 2022151438 A JP2022151438 A JP 2022151438A JP 2021081962 A JP2021081962 A JP 2021081962A JP 2021081962 A JP2021081962 A JP 2021081962A JP 2022151438 A JP2022151438 A JP 2022151438A
- Authority
- JP
- Japan
- Prior art keywords
- otitis
- conchitis
- tympanitis
- treating
- externa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
本発明は、外耳炎と中耳炎と内耳炎の治療薬に関する。TECHNICAL FIELD The present invention relates to therapeutic agents for otitis externa, otitis media and otitis labyrinth.
外耳炎と中耳炎と内耳炎を有効に治療する薬がない。There is no medicine that effectively treats otitis externa, otitis media and otitis labyrinth.
外耳炎と中耳炎と内耳炎の治療薬を提供することを目的とする。The object is to provide a remedy for otitis externa, otitis media and otitis labyrinth.
本発明の目的を達成するため、次の構成を採用する。
外耳で炎症が起こった状態を外耳炎、中耳で炎症が起こった状態を中耳炎、内耳で炎症が起こった状態を内耳炎となります。
変性剤を人体に投入することにより、炎症の原因である身体に侵入した細菌やウイルスや寄生虫などのＤＮＡとＲＮＡを壊すことにより増殖を防ぎ、外耳炎と中耳炎と内耳炎の治療をする。
細菌、ウイルス、寄生虫などの外耳炎と中耳炎と内耳炎の病原体は、核酸を持っている。
核酸とは、ＤＮＡとＲＮＡのことである。
ＤＮＡとＲＮＡは塩基間で水素結合しているが、変性剤を加えてアルカリ性にすると、水素イオンを放出するため変性し、ＤＮＡとＲＮＡの塩基間の水素結合が壊れる。
変性剤を加えてＤＮＡとＲＮＡを壊すことにより、細菌やウイルスや寄生虫などの増殖を防ぐことができるため、変性剤という外耳炎と中耳炎と内耳炎の治療薬となる。
外耳と中耳と内耳を標的とする変性剤を有効成分とするリポソーム医薬品として、人体に投与する方法もある。In order to achieve the objects of the present invention, the following configuration is adopted.
Inflammation of the outer ear is called otitis externa, inflammation of the middle ear is called otitis media, and inflammation of the inner ear is called labyrinthitis.
By injecting a denaturing agent into the human body, the DNA and RNA of bacteria, viruses, parasites, etc. which have invaded the body causing inflammation are destroyed to prevent their proliferation, thereby treating otitis externa, otitis media and otitis inner.
Pathogens of otitis externa, otitis media, and otitis labyrinth, such as bacteria, viruses, and parasites, carry nucleic acids.
Nucleic acids refer to DNA and RNA.
DNA and RNA are hydrogen-bonded between bases, but when a denaturing agent is added to make them alkaline, hydrogen ions are released and they are denatured, breaking the hydrogen bond between bases of DNA and RNA.
By adding a denaturing agent to destroy DNA and RNA, the proliferation of bacteria, viruses, parasites, etc. can be prevented.
There is also a method of administering to the human body as a liposome drug containing, as an active ingredient, a modifying agent that targets the outer, middle, and inner ear.
変性剤という外耳炎と中耳炎と内耳炎の治療薬を人体に投与することにより外耳炎と中耳炎と内耳炎を治療する。代表的な変性剤は、尿素薬がある。Otitis externa, otitis media, and otitis interna are treated by administering denaturing agents for otitis externa, otitis media, and otitis interna to the human body. A representative denaturant is a urea drug.
変性剤という外耳炎の治療薬を外耳に注入する。
変性剤という中耳炎の治療薬を手術により、中耳に注入する。
変性剤という内耳炎の治療薬を手術により、内耳に注入する。
外耳と中耳と内耳を標的とする変性剤を有効成分とするリポソーム医薬品として、飲み薬として飲むか、注射により投与する。
代表的な変性剤は、尿素薬がある。A drug called a denaturant is injected into the outer ear to treat otitis externa.
A denaturant, a drug used to treat otitis media, is surgically injected into the middle ear.
A denaturant, a drug used to treat labyrinthitis, is surgically injected into the inner ear.
As a liposomal drug containing a degenerative agent that targets the outer, middle, and inner ear as an active ingredient, it is taken orally or administered by injection.
A representative denaturant is a urea drug.
特願２０２０－１５５８６２Patent application 2020-155862
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081962A JP2022151438A (en) | 2021-03-26 | 2021-03-26 | Agents for treating conchitis and tympanitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081962A JP2022151438A (en) | 2021-03-26 | 2021-03-26 | Agents for treating conchitis and tympanitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022151438A true JP2022151438A (en) | 2022-10-07 |
Family
ID=83464220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021081962A Pending JP2022151438A (en) | 2021-03-26 | 2021-03-26 | Agents for treating conchitis and tympanitis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2022151438A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510657A (en) * | 1998-04-01 | 2002-04-09 | ノクタ・ピーティワイ・リミテッド | Methods of treating contaminated products and articles |
| JP2002516265A (en) * | 1998-05-27 | 2002-06-04 | ユーロセルティク ソシエテ アノニム | Formulations for applying anti-inflammatory agents, especially antiseptics and / or wound healing promoters, to the upper respiratory tract and / or ear |
| JP2012519175A (en) * | 2009-02-27 | 2012-08-23 | フォーサイト・バイオセラピューティクス・インコーポレーテッド | Otological composition useful for the treatment of infections of mammalian inner ear and outer ear |
-
2021
- 2021-03-26 JP JP2021081962A patent/JP2022151438A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510657A (en) * | 1998-04-01 | 2002-04-09 | ノクタ・ピーティワイ・リミテッド | Methods of treating contaminated products and articles |
| JP2002516265A (en) * | 1998-05-27 | 2002-06-04 | ユーロセルティク ソシエテ アノニム | Formulations for applying anti-inflammatory agents, especially antiseptics and / or wound healing promoters, to the upper respiratory tract and / or ear |
| JP2012519175A (en) * | 2009-02-27 | 2012-08-23 | フォーサイト・バイオセラピューティクス・インコーポレーテッド | Otological composition useful for the treatment of infections of mammalian inner ear and outer ear |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Suresh et al. | An update on recent developments in the prevention and treatment of Staphylococcus aureus biofilms | |
| US10105389B1 (en) | Method and compositions for treating cancerous tumors | |
| JP2022151438A (en) | Agents for treating conchitis and tympanitis | |
| Gemmeke et al. | Folliculitis decalvans of the scalp: response to triple therapy with isotretinoin, clindamycin, and prednisolone | |
| C Liau et al. | The impact of COVID-19 pandemic on cancer patients | |
| JP2022151437A (en) | Agents for treating retinitis | |
| JP2022151439A (en) | Agents for treating rhinitis | |
| JP2022151436A (en) | Agents for treating meningitidis and encephalitis | |
| JP2022151430A (en) | Agents for treating cholecystitis | |
| JP2022151427A (en) | Agents for treating esophagitis | |
| JP2022151431A (en) | Agent for treating enteritis | |
| JP2022124985A (en) | Pneumonia therapeutic drugs | |
| JP2022151440A (en) | Agents for treating arthritis | |
| JP2022151428A (en) | Agent for treating nephritis | |
| JP2022151429A (en) | Agents for treating pancreatitis | |
| JP2022151433A (en) | Agents for treating cystitis | |
| JP2022151432A (en) | Agents for treating myocarditis and pericarditis | |
| JP2022146830A (en) | Therapeutic agent for retinal detachment | |
| JP2022151434A (en) | Agents for treating dermatitis | |
| JP2022151423A (en) | Agents for treating disc herniation | |
| JP2022151426A (en) | Agents for treating upper respiratory inflammation | |
| JP2022140193A (en) | Therapeutic agent for rheumatic diseases | |
| JP2022140194A (en) | Therapeutic agent for connective tissue diseases | |
| JP2022151441A (en) | Agents for treating myositis and fasciitis | |
| JP2022140190A (en) | Therapeutic agent for autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210713 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220719 |